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Abstract
Squamous cell carcinoma (SCC) is the most common neoplasm in organ transplant recipi-
ents (OTR) on long-term immunosuppression and occurs 60- to 100-fold more frequently
than in the general population. Here, we present the receptor for advanced glycation end
products (RAGE) and S100A8/A9 as important factors driving normal and tumor keratino-
cyte proliferation. RAGE and S100A8/A9 were transcriptionally upregulated in SCC com-
pared to normal epidermis, as well as in OTR compared to immunocompetent patients (IC)
with SCC. The proliferation of normal and SCC keratinocytes was induced by exposure to
exogenous S100A8/A9 which in turn was abolished by blocking of RAGE. The migratory ac-
tivities of normal and SCC keratinocytes were also increased upon exposure to S100A8/
A9. We demonstrated that exogenous S100A8/A9 induces phosphorylation of p38 and
SAPK/JNK followed by activation of ERK1/2. We hypothesize that RAGE and S100A8/A9
contribute to the development of human SCC by modulating keratinocyte growth and migra-
tion. These processes do not seem to be impaired by profound drug-mediated immunosup-
pression in OTR.
Introduction
Squamous cell carcinoma is a common skin neoplasm characterized by infiltrative, destructive
growth and metastasis. It is the most common malignant neoplasm in organ transplant recipi-
ents on long-term immunosuppression and occurs 60- to 100-fold more frequently than in the
general population [1]. The early recognition of SCC is important because the neoplasm may
acquire the ability to metastasize. Actinic keratoses (AKs) are considered by some as precancer-
ous lesions, while others consider them an incipient form of SCC [2]. Studies have
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demonstrated that approximately 8% of all AKs will progress to invasive SCC in the general
population [3], and potentially more in OTR. Recognition and treatment of AK are important
for the prevention of neoplasm progression. It is well known that AK is surrounded by a peritu-
moral inflammatory infiltrate before development of invasive SCC, also observed in OTR
under immunosuppression [4–5]. Anti-tumour defence by the immune system seems to play
an important role on one side. On the other side, chronic sustained inflammation seems to cre-
ate a pro-tumorigenic environment [6]. Such smoldering inflammatory mechanisms in the
skin may be at least in part mediated by RAGE and S100A8/A9 [7–10].
RAGE is a multi-ligand member of the immunoglobulin superfamily of cell surface mole-
cules [11–13] and is implicated in inflammation and cancer [14–18]. RAGE ligation activates
important signal transduction pathways involved in tumorigenesis and inflammatory re-
sponses such as the mitogen activated protein kinase (MAPK) family (p38, Erk1/2 and JNK)
and Rho GTPases (cdc42 and rac) [19–22]. To the spectrum of RAGE ligands belongs the S100
family of proteins (calgranulins) including S100A12 [23], S100A9 [24–26] and S100A8/A9 het-
erodimer [19, 27, 28]. They activate cellular processes and cell migration, and have properties
similar to proinflammatory cytokines [29–32]. S100A8 and S100A9 are secreted by neutrophils
and activated monocytes [33–34] and induce activation of NF-κB [31, 35, 36]. They are associ-
ated with chronic inflammation [37–39] and cancer [10, 39–43].
Up to now the role of RAGE-S100A8/A9 signaling in keratinocytes in SCC formation has
not been investigated. Here, we analyze the involvement of these proteins in the development
of human SCC.
Results
RAGE, S100A8 and S100A9 are expressed in SCC of OTRs and IC
Epidermal mRNA expression of S100A8 and S100A9 differs between OTR and IC with
invasive SCC. The mRNA expression level of RAGE in whole skin was similar in normal
skin, IC SCC and OTR SCC. S100A8 and S100A9 mRNA expression was increased only in
SCC of IC versus normal skin (Fig. 1A). In the epidermal fraction, however, the expression of
RAGE, S100A8 and S100A9 was increased in invasive as well as in in-situ SCC of IC and OTR,
all compared to normal epidermis (Fig. 1B).
Expression of RAGE and S100A8/A9 in SCC and normal skin on protein level. The ex-
pression of RAGE and the S100A8/A9 complex on protein level was analyzed by immunohis-
tochemistry. Although the analysis is semi-quantitative, both proteins were clearly upregulated
in invasive or in situ SCC of IC and OTR in comparison to healthy skin (Fig. 2). We did not de-
tect a differential protein expression of RAGE and S100A8/A9 between the OTR and
IC groups.
Endogenous S100A8/A9 is involved in cellular proliferation
Using ELISA specific for S100A8/A9, we detected that normal keratinocytes secrete S100A8/
A9. In comparison to SCC-derived keratinocytes, normal keratinocytes showed lower levels of
spontaneous S100A8/A9 secretion (Fig. 3A). The direct blockade of RAGE using a specific neu-
tralizing anti-RAGE antibody resulted in a reduction of cellular proliferation by 20–25%
(Fig. 3B). This suggests that the endogenous production of S100A8/A9 and RAGE signaling
contributes to keratinocyte proliferation.
S100A8/A9, RAGE and Squamous Cell Carcinoma of the skin
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Fig 1. Differential expression of RAGE, S100A8 and S100A9 on transcriptional level in whole skin and epidermis. Expression of RAGE, S100A8 and
S100A9 on transcriptional level. The expression was assessed by real-time PCR using specific primers for RAGE, S100A8 and S100A9. The expression
level was normalized to 36B4 housekeeping gene. a: whole skin: No significant difference of RAGE expression was detected within or among the groups.
S100A8/A9, RAGE and Squamous Cell Carcinoma of the skin
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Keratinocytes proliferate in response to exogenous S100A8/A9
Cells were seeded in 96 well plates and exposed for 24 hours to purified S100A8/A9 at concen-
trations between 0.01–1μg/ml. All normal, AK and SCC-derived primary keratinocytes re-
sponded with increased proliferation ranging from 30% to 70% after 24 hours exposure to
S100A8/A9 as revealed by BrdU assay (Fig. 4A). Induced BrdU incorporation by S100A8/A9
was also detected by flow cytometry (Fig. 4B). The total RAGE expression was analyzed by
FACS and western blotting (S1 Fig. A, B).
Direct blockade and knockdown of RAGE reduce cellular proliferation
Keratinocyte proliferation following S100A8/A9 exposure was abolished by blockade of RAGE
using a functional blocking antibody (Fig. 5A). A reduction of cellular growth by 80% was de-
tected also when shRNA specific for RAGE was used (Fig. 5B). Proliferation was not influenced
by stimulation of shRAGE-transfected keratinocytes with recombinant S100A8/A9. Using the
antibody HTA125 blocking TLR4, a potentially important receptor for S100A8/A9, prolifera-
tion was not impaired following exposure of keratinocytes to S100A8/A9 (Fig. 5C).
S100A8/A9 induces migration of normal and SCC-derived keratinocytes
The effect of S100A8/A9 on the ability of normal and SCC-derived keratinocytes to migrate in
vitro was investigated using scratch assay. An increase in the number of migrated cells was de-
tected 15 h after scratching (between 60–100%) in both normal and SCC-derived keratinocytes
in the presence of 0.01 and 0.1μg/ml S100A8/A9 (Fig. 6 A, B). At 24 hours after scratching, the
difference was no longer observed.
Exogenous S100A8/A9 induces RAGE surface expression and MAPK
phosphorylation
Exogenous S100A8/A9 induced rapid and transient increase in RAGE surface expression 30
min after S100A8/A9 stimulation and reduced it 1 hour after induction (Fig. 7A), which under-
lines the stimulation of S100A8/A9 through RAGE. To clarify the mechanism of S100A8/A9
we further investigated the phosphorylation of p38, ERK1/2 and JNK/SAPK after stimulation
with S100A8/A9 (Fig. 7B). SCC-derived keratinocytes showed a prolonged activation of p38
phosphorylation in comparison to normal keratinocytes whereas the phosphorylation of p38
was slightly decreased 15 min after treatment. The phosphorylation of ERK1 decreased slightly
15–30 min after exposure to S100A8/A9 in both PK and SCC in comparison to unstimulated
cells (Fig. 7B, S2 Fig.). An increase in the phosphorylation rate of ERK 1 was detected at later
time intervals (45–60 min). SCC cells reacted with a phosphorylation of SAPK/JNK 15 minutes
after exposure to S100A8/A9, whereas in normal keratinocytes phosphorylation of SAPK/JNK
was not detected.
Discussion
Normal whole skin and fully excised SCC express RAGE, S100A8 and S100A9 mRNA in simi-
lar amounts, with only minor increases for S100A8 and S100A9 in IC SCC, while other inflam-
matory factors such as NFkB, CCL3, CCL2, Cox2, TGFß and MMP9 do differ from normal
S100A8 and S100A9mRNAs are increased only in IC patients with invasive SCC versus normal skin (*p<0.05). b: epidermis: The expression of RAGE,
S100A8 and S100A9 transcripts was significantly increased in OTR and IC patients with invasive or in situ SCC versus normal epidermis (***p<0.001).
Significant difference in the expression of S100A8 and S100A9 was also detected between the IC and OTR groups with invasive SCC (*p<0.05; **p<0.01).
doi:10.1371/journal.pone.0120971.g001
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Fig 2. Differential expression of RAGE and S100A8/A9 on protein level in whole skin. The expression level was analysed by immunochistochemistry
using specific anti human S100A8/A9 and anti human RAGE antibodies. The expression was tested in 5 patient samples per group (IC and OTR with in situ
or invasive SCC). a: Expression of RAGE and S100A8/A9 in IC and OTR patients with in situ SCC in comparison to normal skin. b: Expression of RAGE and
S100A8/A9 in IC and OTR patient with invasive SCC in comparison to normal skin.
doi:10.1371/journal.pone.0120971.g002
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skin to SCC (data not shown). This is probably due to the heterogeneous cell population pres-
ent in whole skin. As reported, S100A8 and S100A9 are predominantly secreted by myeloid
cells, but also by epithelial cells and keratinocytes during inflammation [27, 32, 33, 44–46]. In
the epidermal compartment, however, both RAGE and S100A8 and S100A9 were strongly
upregulated at mRNA and protein level already in intraepithelial lesions, suggesting an early
role in SCC development. No additional difference was observed when comparing normal epi-
dermis and SCC from IC and OTR patients, which suggests a role for RAGE and S100A8/A9
not impaired by commonly used immunosuppressive drugs. Previous studies in our group
demonstrated that immunosuppressive agents such as Prednisolone and Cyclosporine are even
able to induce S100A8/A9 expression in keratinocytes [43]. In support of our results, other re-
ports showed that S100A8 and S100A9 were among the genes upregulated in SCC in compari-
son to normal skin [47]. Moreover, S100A8 and S100A9 were found to be upregulated in
defined parts of dysplasia/cancer regions and in the invasion nests in SCC sections [48].
Fig 3. Endogenous S100A8/A9 is involved in cellular proliferation. a: Spontaneous secretion of S100A8/
A9 from normal and SCC-derived keratinocytes. Normal and SCC-derived keratinocytes were grown in 96
well plates for 24 hours. Afterwards, supernatant was collected and preceded for the assessment of secreted
S100A8/A9 using specific ELISA for S100A8/A9. b: Blockade of RAGE using anti RAGE blocking antibody
reduces spontaneous proliferation of keratinocytes. Normal and SCC-derived keratinocytes were incubated
with a blocking anti-RAGE antibody (8ug/100μl) for 24 hours. A decrease of the proliferation rate was
detected (20–30%) based on the BrdU incorporation (t-test *p = 0.002). All the results are presented as
percentage deviation from corresponding control and represent the mean +/- SD of duplicate values.
doi:10.1371/journal.pone.0120971.g003
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In summary, RAGE and its ligand S100A8/A9 seem active in SCC both in the setting of im-
munocompetence and immunosuppression, where immunosuppressive agents do not subdue
the RAGE-S100A8/A9 axis but might potentially accentuate it.
To investigate the functional role of S100A8/A9 and RAGE, we generated primary keratino-
cyte cell cultures derived from normal skin and from lesions of patients with in situ (AK) or in-
vasive SCC. Similar to other reports, we observed that low, rather than high concentrations of
exogenous S100A8/A9 were sufficient to induce cellular proliferation [49, 50]. A potential
function of S100A8/A9 as a driving factor for cell proliferation was reported in human breast
cancer cells [19] and neonatal keratinocytes [51]. Correspondingly, we see S100A8/A9 as a
driving factor for keratinocyte proliferation in human normal skin and SCC. Exogenous
S100A8/A9 induced higher proliferation in normal keratinocytes in comparison to SCC kerati-
nocytes unrelated to differential RAGE expression. We summarize that a differential dose-re-
sponse relationship between the expression level of RAGE and S100A8/A9 and proliferation is
hard to demonstrate due to several confounding factors such as origin of cells, number of cell
passages, difference in cell signaling machinery between normal keratinocytes and different
SCCs studied. Importantly, RAGE receptor blocking abolished the proliferative effect of exoge-
nous S100A8/A9, indicating a critical role for RAGE. The possibility of additional receptors for
S100A8/A9 on keratinocytes being involved such as TLR4 remains, as the secreted amount of
Fig 4. Exogenous S100A8/A9 induces keratinocyte proliferation. a: Assessment of the proliferation by BrdU assay. To assess the role of S100A8/A9 in
normal primary, AK and SCC cultures, they were treated with purified S100A8/A9 for 24 hours and proliferation was assessed by BrdU incorporation. The
induction of cellular proliferation was between 30–70% (2 way Anova, p<0.0001). b: Assessment of the proliferation by the incorporation of BrdU analysed by
flow cytrometry. Normal keratinocytes were treated with S100A8/A9 (10ng/ml) and BrdU for 24 hours. Afterwards cells were fixed in 4% PFA, permeabilized
with 0.5% Triton and stained for RAGE and BrdU using the antibodies mentioned above. The differential BrdU incorporation was compared to untreated cell.
doi:10.1371/journal.pone.0120971.g004
S100A8/A9, RAGE and Squamous Cell Carcinoma of the skin
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S100A8/A9 from SCC cells was significantly higher than the decrease of the proliferation rate
after RAGE blockade. However, we did not detect a decrease of cellular proliferation after the
blockade of TLR4 by a specific blocking antibody. Our results correlate with other published
data, where a relation between tumor growth and RAGE/S100A8/A9 axis was reported [15,
28]. Local production of S100A8/A9 within the epidermis may thus be a driving force for the
proliferation of keratinocytes. Next to proliferation, our observation of increased migration
suggests a role of S100A8/A9 in keratinocyte motility and a potential invasion.
Fig 5. The receptor RAGE critically mediates the cellular response to S100A8/A9. a: Direct blockade by a specific RAGE blocking antibody reduces
cellular proliferation. RAGE dependent proliferation was analyzed in normal primary, AK and SCC cells. Cells were incubated for 1 hour with a blocking anti-
RAGE antibody (80μg/ml, as recommended by manufacturer) followed by S100A8/A9 stimulation for additional 24 hours. The differences in the proliferation
after the blockade were assessed by BrdU incorporation (1 way Anova, Bonferroni`s Multiple test, **p<0.05, ***p<0.05). b: Knockdown of RAGE using
shRNA reduces cellular proliferation. The knockdown studies were performed using specific lentiviral shRNA against RAGE. Primary keratinocytes were
infected by shRAGE and sh control viral particles. Selection of positive clones was performed by puromycine selection. Cells were grown to optimal
confluence and were stimulated with 10ng/ml S100A8/A9.Cells with RAGE knockdown showed a delay in proliferation in comparison to control as assessed
by BrdU (70%) (1 way Anova, Bonferroni`s Multiple test p****<0.0001) and microscope images. Exogenous S100A8/A9 did not induce proliferation of
shRAGE keratinocytes, but only in the control. c: Blocking TLR4 using specific blocking antibody (HTA125) does not impair cellular proliferation. AK cells
were treated with a specific blocking TLR4 antibody (HTA125). AK cells were grown for 24 hours in the presence of HTA125 antibody (1μg/ml) and S100A8/
A9 (10ng/ml). For detection of the cellular proliferation rate BrdU proliferation assay was performed.
doi:10.1371/journal.pone.0120971.g005
S100A8/A9, RAGE and Squamous Cell Carcinoma of the skin
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Normal and SCC-derived keratinocytes showed distinct phosphorylation of JNK after
S100A8/A9 stimulation, which is probably due to a different response to S100A8/A9, based on
their origin (tumor vs. normal cells). Studies concerning the role of RAGE-S100A8/A9 axis in
the induction of MAPK, JNK or p38 pathways show that depending on the cell type, a differen-
tial phosphorylation pattern of these kinases is observed. In breast and colon cancer cells,
S100A8/A9 is found to induce phosphorylation of ERK and JNK [19, 35, 52]. These results
consider a role for ERK phosphorylation in RAGE-S100A8/A9 axis. Similarly, we observed
phosphorylation of ERK in both normal and SCC keratinocytes and suggest that it may con-
tribute to the proliferation and migration after S100A8/A9 stimulation. It is also possible that
this kinase profile is due to a crosstalk between the MAPK, JNK and p38 pathways, regulating
the balance between apoptosis (p38, JNK) and proliferation (ERK1/2) [53].
S100A8/A9 may act as a growth factor similar to chemokines. A chemokine-like function of
S100A8/A9 was described in terms of enhancement of leukocyte recruitment to inflammatory
sites [54–56]. Keratinocytes may be the initial source for S100A8/A9, in turn attracting inflam-
matory cells. The effect of S100A8/A9 on cell growth may be mediated by cytokine induction.
Recently, it was reported that exogenous S100A8/A9 induces the expression of inflammatory
Fig 6. Exogenous S100A8/A9 inducesmigration of normal and SCC-derived primary keratinocytes. a,
b: Cells were treated with different concentrations of purified S100A8/A9 (0.01–1 μg/ml) for 15h. The
assessment of the migratory potential was analyzed by scratch assay where the number of migrated cells
was analyzed. The migration of both normal and SCC-derived keratinocytes was increased significantly
(between 60–100% depending on cell type) when 0.01 and 0.1μg/ml of S100A8/A9 were used (t-test, PK,
*p = 0.003, *p = 0.004; SCC, *p = 0.0014,*p = 0.0015).
doi:10.1371/journal.pone.0120971.g006
S100A8/A9, RAGE and Squamous Cell Carcinoma of the skin
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Fig 7. Exogenous S100A8/A9 induces RAGE surface expression and MAPK phosphorylation. a: Rapid and transient induction of RAGE surface
expression after stimulation with S100A8/A9. Normal keratinocytes were induced with an exogenous S100A8/A9 (10ng/ml) in time intervals of 30 and 60
minutes. Afterwards cells were stained with the specific goat polyclonal anti RAGE antibody and a secondary FITC-conjugated antibody for analysis of both
surface and total RAGE expression before and after S100A8/A9 treatment. Total expression of RAGE was analyzed prior to cell permeabilization with PFA
and followed by blocking step with 1% BSA. As controls isotype control antibody and untreated cells were used. b: Exogenous S100A8/A9 induces
S100A8/A9, RAGE and Squamous Cell Carcinoma of the skin
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cytokines such as IL-8, IL-6 and TNF from neonatal keratinocytes [51] and macrophages [31,
34, 57]. While we hypothesize that S100A8/A9 influences the migration and invasion in SCC,
its effect on metastasis remains controversial. Some reports show an inhibitory effect of
S100A8/A9 on metastasis of human cervical cancer cells [58]. Clarifying the role of S100A8/A9
in the metastasis of SCC will be an important next step.
Organ transplant recipients suffer from SCC with a 60- to 100-fold increased incidence
compared to the general population. In spite of their chronic immunosuppressive medication,
a considerable amount of inflammation can still be observed in the local tumor microenviron-
ment [4]. While low-level inflammation still occurs in the setting of chronic immunosuppres-
sion, tumor rejection by the immune system is impaired in organ transplant recipients,
reflected by changes in the inflammatory microenvironment of SCC in OTR [59], [5]. We ob-
served that the expression levels of RAGE and S100A8/A9 in OTR were still increased in com-
parison to healthy skin. It is tempting to speculate that S100A8/A9 induced by UV damage in
sun-exposed skin could drive keratinocytes via RAGE to proliferate and migrate, eventually
contributing to the greatly increased SCC formation in OTR.
In summary, we present evidence for a direct effect of S100A8/A9 on the proliferation and
migration of normal human keratinocytes and keratinocytes originating directly from SCC le-
sions, suggesting a prominent role of S100A8/A9 on SCC formation, with RAGE as important
target. This role of S100A8/A9 seems maintained in OTR. Targeting S100A8/A9 or RAGE may
be of clinical benefit for SCC prevention and treatment.
Materials and Methods
Ethical considerations
The use of clinically indicated biopsy material for the study was approved by the ethical com-
mittee of the Canton of Zürich, Switzerland and was previously published: [60–64]
Tissue samples
Invasive SCC from organ transplant recipients (n = 13) and immunocompetent patients
(n = 19) as well as in-situ SCC from OTRs and immunocompetent patients (1 and 5 respective-
ly) were obtained at the time of surgery. Normal skin was obtained from abdominoplastic re-
constructive surgery (n = 5). All specimens’ diagnoses were confirmed by a board-certified
dermatohistopathologist. 4mm punch biopsies from the SCC or normal skin area were placed
in preheated PBS at 60°C for 45 seconds, and then chilled on ice in for 1 minute, followed by
mechanical separation of epidermis and dermis. The epidermis was then homogenized in TRI-
zol Reagent (Invitrogen, Basel, Switzerland), and stored at −80°C
RNA extraction and reverse transcription. Total RNA was isolated using TRIzol Reagent
following the instructions provided by the manufacturer. cDNA was synthesized using a Re-
verse Transcription System kit (Promega, Dübendorf, Switzerland) following the protocol pro-
vided. After 1:4 dilution with sterile water, cDNA was stored at −20°C and used as template for
subsequent quantitative real-time polymerase chain reaction (RT-PCR).
phosphorylation of MAPKs. Normal and SCC-derived keratinocytes were seeded in 6cm dishes in 50% confluence. Cells were starved for 18 h and
stimulated afterwards with S100A8/A9 (10ng/ml) for different time intervals (0–60min). Cell lysates were collected after each time interval and the alteration of
the phosphorylation of ERK1/2, p38 and SAPK/JNK was analyzed by western blot using the indicated antibodies.
doi:10.1371/journal.pone.0120971.g007
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Immunohistochemical analysis (IHC)
RAGE and S100A8/A9 protein expression was analyzed in formalin-fixed paraffin-embedded
skin samples obtained from the archives of the Dermatology Department of University Hospi-
tal Zurich. The expression was tested in in-situ and invasive forms of SCC derived from OTRs
and immunocompetent patients (5 samples per group)
Four μm thick sections were deparaffinized by 2x10 min incubation in Xylol and then rehy-
drated in a descending ethanol series (from 100% ethanol to PBS). For antigen retrieval, citrate
buffer pH 6 (0.05% Tween 20) was pre-heated to 95°C, and the sections were kept at this tem-
perature for 15 min. They were then allowed to slowly cool down to room temperature, and
were then transferred to PBS. Blocking of nonspecific antibody binding was achieved by incu-
bating the sections in PBS containing 2.5% of normal rabbit serum for RAGE staining or 2.5%
normal goat serum for S100A8/A9. The staining was performed using anti-human RAGE poly-
clonal goat antibody (R&D Systems Europe LtD) and anti-human S100A8/A9 mouse monoclo-
nal antibody (clone #27E10) (BMA Biomedicals, Augst, Switzerland) in a working dilution 1:50
(anti-RAGE) and 1:100 (anti-S100A8/9) in Antibody Diluent (Dako, Hamburg, Germany).
Overnight incubation was performed in a humid chamber at 4°C. For detection of antibody
binding to S100A8/A9 the Dako REAL Detection System AP/RED was used, and for detection
of antibody biding to RAGE the Vectastain ABC-APKit (Vector Laboratories, Burlingame, CA,
USA) was used according the manufacturers` protocol. The slides were briefly soaked in hema-
toxylin and then left under running tap water for 10 min. The slides were mounted with
Mounting Medium (Dako).
Generation of primary keratinocyte cultures derived from healthy
individuals and SCC patients
Single keratinocytes were isolated from 3–4mm punch biopsies following the standard protocol
for generation of primary keratinocyte cultures (CELLnTEC, Bern, Switzerland). For sufficient
separation of the epidermis and dermis the punch biopsies were incubate overnight at 4°C in
keratinocyte medium (Progenitor Cell Targeted (PCT) epidermal keratinocyte medium CnT07
(CELLnTec) with Dispase II (Roche). Afterwards the epidermal part of the skin was incubated
in trypsin (room temperature, 30 min) to insure efficient isolation of single keratinocytes.
Freshly isolated cells were washed with medium and then transferred into CnT07 medium for
a continuous incubation (37°C, 5%CO2).
RNA extraction and Real Time PCR
RNA was extracted using the TRIzol reagent (Invitrogen, Basel, Switzerland) following the pro-
tocol provided by the manufacturer. cDNA was synthesized from 0.5μg total RNA using a Re-
verse Transcription system kit (Promega). Specific primers for RAGE (Quantitect Primer assay,
Quiagen AG, Hombrechtikon, Switzerland), S100A8 (fwd GGGAATTTCCATGCCGTCT, rev
CCTTTTTCCTGATATACTGAGGAC), S100A9 (fwd CTGTGTGGCTCCTCGGCT, rev
GCGTTCCAGCTGCGACAT), 36B4 (fwd GCAATGTTGCCAGTGTCTGT, rev
GCCTTGACCTTTTCAGCAAG) and K14 (Quantitect Primer assay, Quiagen) were used. Real
Time PCR was performed using Light Cycler FastStart DNAMaster Sybr Green 1 kit (Roche,
Switzerland).
Statistical analysis
Statistical analysis was performed using Microsoft Excel 2000 and GraphPad Prism 5.0 for
Windows. The gene expression by real-time RT-PCR was quantified using the comparative
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threshold cycle (Ct) method [65]. Statistical evaluation was performed using the 2 way and
one-way ANOVA test followed by Bonferroni’s Multiple Comparison Test, or t-test. P values
less than 0.05 were considered statistically significant.
Flow cytometry
FACS analysis. The assessment of the surface RAGE expression after induction with
S100A8/A9 was performed using FACS analysis. Cells were detached using 4mM ETDA in
PBS, washed with PBS, incubated with a specific goat anti-human RAGE antibody (R&D Sys-
tems) and visualized by specific donkey-anti goat FITC labeled secondary antibody (Santa
Cruz, Biotechnology) in PBS at 4°C for 1h under gentle shaking conditions. The analysis was
performed on 10 000 gated live cells together with a control (unstained and the secondary-
FITC conjugated antibody) using FACSDIVA software (BD Biosciences, Basel, Switzerland).
Double staining for RAGE and BrdU was performed using the specific RAGE antibody and
specific mouse anti BrdU antibody (Millipore). Before the staining cells were fixed with 4%
PFA for 20min, followed by permeabilization with 0.5% Triton X, washed 3 times and pro-
ceeded for staining.
BrdU proliferation assay
Cells were seeded in 96 well plates in serum-free CnT07 medium in a cell density of 4.103/well.
Incubation with purified S100A8/A9 protein was performed using concentrations between
0.01–1ug/ml for 24h. Blocking goat anti-human RAGE antibody (R&D systems) was added 1h
prior to S100A8/A9 exposure. Cell proliferation was measured using the BrdU proliferation
assay (Millipore) according to the manufacturer`s instruction. The percentage of cell prolifera-
tion was calculated using the equation: (mean OD of treated cells/mean OD of control cells) X
100. Purified S100A8/A9 protein was provided by Thomas Vogl, (Institute for Immunology,
University of Münster, Germany), [31, 66]. Human S100A8/A9 was extracted from human
granulocytes (c = 1,39 mg/ml, buffer: HBS, pH 7,4; source: granulocytes from 12 human buffy
coats). No endotoxin contamination was detected by Limulus assay (LAL). The purity of the
protein was confirmed by Coomassie blue staining after SDS electrophoresis.
Immunoblotting
Normal and SCC-derived keratinocytes were grown in 6cm dishes in 60% confluence. After-
wards cells were stimulated with S100A8/A9 (10ng/ml) for different time intervals (0–60 min).
Cells were lysed in RIPA buffer (conventional recipe). Cell lysates were collected after each
time interval and subjected to PAGE, followed by immunoblotting. The phosphorylation of
ERK1/2, p38 and SAPK/JNK was detected by specific rabbit anti phospho-ERK1/2, -p38 and
-SAPK JNK antibodies (Cell Signaling Technology). The non-phosphorylated form of the ki-
nases were detected using specific rabbit anti- ERK1/2, p38 (Cell SignallingTechnology) and
anti SAPK/JNK (Santa Cruz, Biotechnology). The loading control actin was detected by specific
anti actin antibody (Santa Cruz, Biotechnology).
RAGE expression in normal and SCC keratinocytes was confirmed by using of specific
human anti RAGE antibody (Millipore).
RNA knockdown study
Primary keratinocytes were infected with RAGE sh lentiviral particals (sc-36374-v) and control
sh viral particals (sc-108080), following the protocol conditions (Santa Cruz Biotechnology).
Positive clones were selected by puromycine selection. Stimulation of shRAGE and sh control
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expressing cells with S100A8/A9 protein was performed when the cells have reached an appro-
priate density. For determination of the effect of RAGE knockdown on cellular proliferation
with a following S100A8/A9 stimulation, BrdU proliferation assay was performed.
Scratch assay
Normal and SCC-derived keratinocytes were grown in 24 well plates until they reached full
confluence and starved for further 15 hours in basal keratinocyte medium without supplements
(CELLnTEC). Scratches were performed using a blue pipette tip. Cells were washed afterwards
2 times with basal keratinocyte medium. Exposure to exogenous S100A8/A9 was performed in
a dose dependent manner using concentrations between 0.01–1μg/ml. Exposure was per-
formed in triplicates for each concentration and control cells. After 15 and 24 hours, respec-
tively, cells were fixed with 4% Paraformaldehyde (Merck, Dietikon, Switzerland), stained with
Diff-Quik kit (Medion-Diagnostics AG, Düdingen, Switzerland), and counted in the whole
scratch. The percentage of migrated cells was calculated as % of control.
Supporting Information
S1 Fig. RAGE expression in normal and SCC-derived keratinocytes. a: Surface and total ex-
pression of RAGE in normal keratinocytes. Surface RAGE expression was analyzed by FACS
using specific anti RAGE antibody and FITC-conjugated secondary antibody. For intracellular
staining cells were permeabilized (4%PFA) and blocked (1% BSA) prior staining with the spe-
cific RAGE antibody. As a control isotype control antibody was used. b: RAGE expression in
normal and SCC derived keratinocytes. Cell lysates from primary normal and SCC keratino-
cytes were set to SDS PAGE electrophoresis and western blotting was performed using specific
primary anti RAGE and secondary HRP-conjugated antibodies. As a loading control additional
staining against actin was performed using specific anti actin antibody.
(TIF)
S2 Fig. Densitometrical quantification of phosphorylated ERK, JNK and p38 proteins ver-
sus control. a: Spot density-based quantification of pERK1/2 versus ERK1/2 and versus load-
ing control (actin). b: Spot density-based quantification of pSAPK/JNK (pp54/p46) versus
SAPK/JNK and versus loading control (actin). c: Spot density-based quantification of pp38 ver-
sus p38 and versus loading control (actin).
(TIF)
S3 Fig. RAGE expression in normal keratinocytes after RAGE knockdown by lentiviral
shRNA. The RAGE expression after knockdown was analyzed on transcriptional level by
qPCR using specific primers for RAGE and compared to sh control.
(TIF)
S4 Fig. S100A8/A9 protein purification. S100A8/A9 has been extracted from granulocytes of
buffy coats. The purity, quantity and quantity of the extracted S100A8/A9 were analyzed by
Coomasie blue staining after SDS gel electrophoresis.
(TIF)
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